) posted earnings per share ('EPS') of 53 cents in the second
quarter of fiscal 2013, edging past the Zacks Consensus Estimate
by a couple of cents. The results were also better than the
year-ago EPS by 26%. Apart from increased sales and higher
margins, a decline in tax rate supported the huge EPS
CAREFUSION CORP (CFN): Free Stock Analysis
EDWARDS LIFESCI (EW): Free Stock Analysis
HANGER ORTHOPED (HGR): Free Stock Analysis
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Revenues soared 13% year over year (up 14% at constant exchange
rates or CER) to $376.5 million, a record high for ResMed. The
top-line comfortably beat the Zacks Consensus Estimate of $365
million. Riding on the back of increasing awareness regarding
sleep-disordered breathing and a vastly under-penetrated and
growing sleep-disorder breathing market, revenues in the Americas
surged 16% to $211.8 million whereas revenues outside the
Americas increased 10% (up 9% at CER) at $164.7 million. Growth
in the overseas market was on account of strong contributions
from Germany, France, the U.K. and Japan.
The company reported domestic flow generator sales of $93.7
million in the quarter, up 16% year over year due to robust sales
of Automatic Positive Airway Pressure ("APAP") systems and
Bi-Level device. Masks and other sales were $118.1 million in the
Americas, up 16% year over year, on the back of higher sales of
the mask product range and persistent growth in accessories.
Outside the Americas, flow generator sales were $108.9 million,
up 9% (up 11% at CER) year over year. Masks and other sales
outside the Americas, were $55.9 million, up 11% (up 16% at CER)
year over year. At CER, worldwide flow generator sales increased
13% year over year, while masks and other increased 16%.
Gross profit in the reported quarter climbed 17.1% to $232.7
million leading to a 210 basis points (bps) expansion in gross
margin to 61.8%. The improvement in gross margin was attributed
to favorable product mix towards higher-margin flow generators
and robust accessory sales. Selling, general and administrative,
and research and development expenses during the quarter
increased 7% (up 8% at CER) to $107.8 million and up 11% (up 11%
at CER) to $30.3 million, respectively. Nevertheless, operating
margin expanded about 420 bps to 24.5% in the quarter.
ResMed exited the quarter with cash and cash equivalents of
$958.3 million compared with $809.5 million at the end of fiscal
2012. Cash flow from operations was $93.6 million in the second
quarter. This depicts solid capital management fundamentals.
ResMed repurchased 1 million shares for $40 million in the second
quarter (13.6 million shares for $391.2 million in fiscal 2012)
and was left with the authorization to repurchase 7.6 million
shares. In fiscal 2013, ResMed intends to purchase at least 2
million shares through its existing share buyback program.
Additionally, the Board declared a quarterly dividend of 17 cents
per share, payable on Mar 19, 2013.
Despite the contagion of economic problems in Europe, the
company's solid underlying growth in the region is encouraging.
Moreover, penetration into the untapped Asia-Pacific market,
primarily in Japan, is another material upside. With a healthy
portfolio of well-regarded solutions to cater to the growing
sleep-disorder market, there is no dearth of positive catalysts
The positive events are reflected in the bullish momentum of the
stock. Though by smaller margins, ResMed inched towards a new
52-week high of $45.62 on the day the results were announced.
With estimates moving higher for the current as well as next
fiscal, the stock carries a Zacks Rank #2 (Buy). Other Zacks Rank
#2 medical stocks are